Cargando...
Using PARP Inhibitors in the Treatment of Patients with Ovarian Cancer
Use of Poly(ADP-Ribose) Polymerase (PARP) inhibitors has greatly increased over the past five years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and...
Gardado en:
| Publicado en: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8240125/ https://ncbi.nlm.nih.gov/pubmed/30535808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0572-7 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|